Town Hall: Booster Shots

ByJoel M. Gelfand, MD, MSCE

ByCarlos del Rio, MD

ByLeonard H. Calabrese, DO

In this episode, Joel M. Gelfand, MD, MSCE, and Leonard H. Calabrese, DO, are joined by Carlos del Rio, MD, as they discuss the use of booster shots in the general population and in patients with underlying autoimmunity.

Welcome from Joel Gelfand, MD, MSCE :10
About Calabrese, del Rio and Gelfand :30
del Rio on the future of the pandemic 1:12
Recommendations for boosters in general population 3:25
What does “immunocompromised” mean in terms of boosters? 6:14
What is an additional dose vs. booster dose? Who’s eligible? 9:24
Summary 14:12
Immunosuppressed patients – degree of severity 16:14
Safety of boosters in general population 17:00
Safety of boosters in those with underlying autoimmunity 18:12
Questions from the audience 22:03
Tweet your questions @DrJoelGelfand, @LCalabreseDO and @CarlosdelRio7 29:24

We’d love to hear from you! Send your comments/questions to Drs. Gelfand, Calabrese and del Rio at covid19podcast@healio.com. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews, @GoHealio, @DrJoelGelfand, @LCalabreseDO and @CarlosdelRio7.

Published by:

Sources/Disclosures

Collapse

Disclosures: Calabrese reports consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Horizon, Janssen, Kiniksa, Eli Lilly & Co., Pfizer, Sanofi-Regeneron and UCB, as well as speaking fees from AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Horizon, Sanofi and UCB. Del Rio reports being an investigator on Moderna and Novavax COVID-19 vaccine studies. Gelfand reports he served as a consultant for Bristol-Myers Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen Biologics, Novartis, Regeneron, UCB (Data Safety and Monitoring Board), Sanofi and Pfizer, receiving honoraria; receives research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Janssen, Novartis, Sanofi, Celgene, Ortho Dermatologics and Pfizer; has received payment for CME work related to psoriasis that was supported indirectly by Eli Lilly and Company and Ortho Dermatologics; and is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma and a deputy editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology.

Read more

Town Hall: Booster Shots

Unmasking COVID19

Related Content